Search Results 791-800 of 16374 for monoclonal antibody

1. A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors - Mayo Clinic

   A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors. Print details. Share; Facebook · Twitter.

2. Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production - Mayo Clinic

   - History of severe hypersensitivity to another monoclonal antibody - Other concurrent cancer or a history of another invasive malignancy within the last 3

3. Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease - Mayo Clinic

   Abnormal specific antibody response to immunization; ... Has received any lymphocyte depleting agents including anti-CD20 monoclonal antibodies, alemtuzumab, ATG ...

4. Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients - Mayo Clinic

   Monoclonal antibodies: Subjects who have received any monoclonal antibody within 5 half-lives of Visit 1. Investigational medications: Subjects who have ...

5. Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L Biliary Tract Cancer (BTC) - Mayo Clinic

   ... monoclonal antibodies (Grade ≥ 3 National Cancer Institute [NCI]-Common ... antibody, or anti-4-1BB antibody is not allowed, inclusive of localized ...

6. A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab - Mayo Clinic

   ... antibody, avelumab, in selected advanced solid tumors. ... Known prior severe hypersensitivity reaction to monoclonal antibodies (grade ≥ 3 by NCI CTCAE v4.

7. Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia - Mayo Clinic

   Participation eligibility · Chemotherapy < 21 days prior to first administration of study treatment and/or monoclonal antibody < 6 weeks prior to first ...

8. Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma - Mayo Clinic

   ... monoclonal antibody specific for the epithelial-cell-derived cytokine thymic stromal lymphopoietin (TSLP), in patients whose asthma remained uncontrolled ...

9. ALPN-202 With PD-1 Inhibition in Advanced Malignancies - Mayo Clinic

   Other monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, antibody-like drugs, cytokines, cell therapies, or radioimmunoconjugates: 4 weeks.

10. Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence - Mayo Clinic

    History of severe hypersensitivity reaction to any monoclonal antibody. Prior malignancy active within the previous 3 years except for locally potentially ...